Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High- Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Conditions: Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms Interventions: Drug: Nab paclitaxel 80 mg/m^2; Drug: Relacorilant 150 mg once daily (QD); Drug: Liposomal doxorubicin 40 mg/m^2; Drug: Paclitaxel 80 mg/m^2; Drug: Topotecan 4 mg/m^2; Drug: Topotecan 1.25 mg/m2; Drug: Nab-paclitaxel 100 mg/m2 IV Sponsor: Corcept Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Research